-
- See Kwok
- Cardiovascular Trials Unit Manchester University NHS Foundation Trust Manchester UK
-
- Safwaan Adam
- Faculty of Biology Medicine and Health, University of Manchester Manchester UK
-
- Jan Hoong Ho
- Cardiovascular Trials Unit Manchester University NHS Foundation Trust Manchester UK
-
- Zohaib Iqbal
- Cardiovascular Trials Unit Manchester University NHS Foundation Trust Manchester UK
-
- Peter Turkington
- Department of Respiratory Medicine Salford Royal NHS Foundation Trust Salford UK
-
- Salman Razvi
- Cardiovascular Research Centre Institute of Genetic Medicine, Newcastle University Newcastle upon Tyne UK
-
- Carel W. Le Roux
- Diabetes Complications Research Centre University College Dublin Dublin Ireland
-
- Handrean Soran
- Cardiovascular Trials Unit Manchester University NHS Foundation Trust Manchester UK
-
- Akheel A. Syed
- Faculty of Biology Medicine and Health, University of Manchester Manchester UK
説明
<jats:title>Summary</jats:title><jats:p>Obesity is an emerging independent risk factor for susceptibility to and severity of coronavirus disease 2019 (COVID‐19) caused by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). Previous viral pandemics have shown that obesity, particularly severe obesity (BMI > 40 kg/m<jats:sup>2</jats:sup>), is associated with increased risk of hospitalization, critical care admission and fatalities. In this narrative review, we examine emerging evidence of the influence of obesity on COVID‐19, the challenges to clinical management from pulmonary, endocrine and immune dysfunctions in individuals with obesity and identify potential areas for further research. We recommend that people with severe obesity be deemed a vulnerable group for COVID‐19; clinical trials of pharmacotherapeutics, immunotherapies and vaccination should prioritize inclusion of people with obesity.</jats:p>
収録刊行物
-
- Clinical Obesity
-
Clinical Obesity 10 (6), 12403-, 2020-08-28
Wiley
